Berberine is a yellow alkaloid found in several plants used in Chinese medicine, including Coptis root, and in goldenseal and barberry. It has been studied for decades in China as a treatment for type 2 diabetes and high cholesterol, and the trial literature is large, mostly Chinese, and mostly positive.

Its recent fame in the West came from social media labeling it a natural alternative to GLP-1 drugs. The trials do not support that framing. What they support is a modest, consistent lowering of blood glucose and lipids in people with diabetes, with gastrointestinal side effects, which is a different and more interesting claim than the one it is sold on.

Berberine activates AMP-activated protein kinase, a cellular energy sensor that metformin also acts through, and inhibits an intestinal enzyme pathway involved in bile acid handling. A 2020 multicenter trial traced part of its glucose effect to the gut microbiome: berberine suppressed a bacterial species that transforms bile acids, and that change tracked the fall in blood sugar. A 2021 study identified a direct effect on insulin secretion via a potassium channel in pancreatic cells. It is poorly absorbed, so much of what it does, it may do in the gut.

Glucose: many trials, consistent direction. A 2021 meta-analysis of 46 randomized trials found berberine, alone or added to standard therapy, lowered HbA1c by about 0.7 percentage points and fasting glucose by about 0.9 mmol/L compared with control, with improvements in insulin resistance, BMI and lipids. A 2015 meta-analysis of 27 trials in 2,569 patients found berberine with lifestyle change outperformed lifestyle change alone, and berberine was no different from oral hypoglycemic drugs when compared head to head.

The best single trial. PREMOTE, a 2020 randomized double-blind placebo-controlled trial across 20 Chinese centers, gave 409 newly diagnosed patients twelve weeks of berberine, probiotics, both or placebo after an antibiotic run-in. HbA1c fell by about one percentage point on berberine against about 0.6 on placebo, with more gastrointestinal side effects on berberine.

The 2008 pilot that started it. In 36 newly diagnosed patients, three months of berberine lowered HbA1c about as much as metformin did, with triglycerides falling too, and a third of patients had transient stomach upset.

Weight. The meta-analyses report small reductions in BMI alongside the glucose effect. Nothing in the literature resembles the weight loss of the drugs it is compared with online.

Gastrointestinal effects, constipation, diarrhea and abdominal discomfort, are common; a third of patients in the 2008 pilot and more of the berberine arm in PREMOTE reported them. Berberine inhibits liver enzymes that metabolize many drugs, including some statins, blood thinners and immunosuppressants, so interactions are a real concern for anyone on regular medicines. It is not advised in pregnancy or breastfeeding, and in newborns it can displace bilirubin and worsen jaundice.

Because its effect is on blood sugar, combining it with diabetes drugs without telling a clinician risks low blood sugar. The trials monitored liver and kidney function and found no damage over three months; longer use is less studied.

In China berberine is a licensed medicine with a long history of use for intestinal infections and, more recently, metabolic disease. In the United States, the United Kingdom and the European Union it is sold as a dietary supplement without review of its claims, and the glucose-lowering claim that the trials actually support is one a supplement label is not allowed to make. The gap between what it is licensed for in one country and sold for in another is wider than for most entries here.